Every Thursday, Wall Street watches a number. Both Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo hit their highest total prescriptions ever in the week ended September 11, according to IQVIA data cited by Citi. The Wegovy pill reached approximately 183,000 total scripts for the most recent reporting period, versus 181,000 the week prior. Foundayo kept climbing, too. The sell side is trading this data like a weekly sports score. Long-term investors should not.
Two Very Different Pills
The Wegovy pill received FDA approval in December 2025, while Foundayo won approval on April 1, 2026. That roughly three-month gap explains most of the prescription gap between them today. But the drugs are structurally different in ways that matter beyond launch timing.
Foundayo offers greater daily flexibility because it can be taken anytime with or without food, whereas the Wegovy pill is taken on an empty stomach in the morning, with at least a 30-minute wait before eating, drinking, or taking other oral medications. Foundayo contains orforglipron, a non-peptide, small-molecule GLP-1 receptor agonist designed for oral delivery. The Wegovy pill relies on semaglutide, the same compound doctors and patients already know from injectable Wegovy, paired with an absorption enhancer.
Both pills are effective for weight loss, but Wegovy showed greater reduction in clinical trials. Novo has cited 16.6% weight loss for the Wegovy pill, while Lilly has reported about 11.1% at 72 weeks for Foundayo at its highest marketed dose. Lilly’s bet is that convenience eventually trumps efficacy for millions of patients who will not maintain a rigid morning fasting routine.
The Scoreboard Hides the Real Story
Q2 earnings told a more complicated story than the weekly scripts suggest. The Wegovy pill had sales of about $494 million in the second quarter, below analysts’ expectations. Foundayo sales also fell short of Wall Street expectations, coming in at $98 million versus a consensus estimate of about $103 million. Both drugs missed. Both companies have more work to do.
Yet the broader GLP-1 market is accelerating, not stalling. Total GLP-1 prescriptions have increased 5.4% over the last four weeks, compared to a 6.8% decline the prior year, a 12-percentage-point swing that Citi attributes to the expansion of oral GLP-1 therapies broadening access to the class and drawing in new patients. The oral pills are not cannibalizing existing injectable demand. They are extending the market. J.P. Morgan has forecast roughly 30 million Americans will be taking a GLP-1 by 2030, up by about 10 million from branded GLP-1 users in 2026.
How to Think About Owning Both
The two companies present genuinely different risk profiles, and that is actually useful for long-term portfolio construction. Lilly carries the stronger business momentum. It reported $23 billion in Q2 revenue, a 48% increase year over year. Full-year 2026 guidance now stands at $85 billion to $87 billion. Novo trades at a significant discount after a rough stretch. Novo announced it will lower the U.S. list price of Wegovy by about 50% and Ozempic by about 35%, effective January 1, 2027, a move that could pressure per-prescription economics while aiming to protect volume. Valuation multiples move around, but the market has generally been valuing Lilly more richly than Novo.
All three major U.S. pharmacy benefit managers now cover Lilly’s obesity portfolio, while the Medicare GLP-1 Bridge program began providing eligible patients access to Foundayo and Zepbound in July. That coverage expansion is what drives durable prescription volume, not any single week’s IQVIA reading.
The Wealth Builder Takeaway
The weekly prescription tracker is a useful indicator, but it is not the investment. The more durable question is whether one company’s pill, or both, becomes a fixture in the medicine cabinets of tens of millions of people over the next decade. On that time horizon, the efficacy edge belongs to Novo, the convenience and pipeline momentum edge belongs to Lilly, and the valuation entry point belongs to Novo by a wide margin. Owning a measured position in each reflects the reality that this market is large enough for two winners, and that no weekly scoreboard will tell you which one that turns out to be.
